| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/30/2001 | US6180114 Therapeutic delivery using compounds self-assembled into high axial ratio microstructures |
| 01/30/2001 | CA2313825A1 Myostatin regulatory region, nucleotide sequence determination and methods for its use |
| 01/25/2001 | WO2001006018A1 Antisense modulation of map kinase kinase 6 expression |
| 01/25/2001 | WO2001006015A1 NOVEL GLYCOSYL SULFOTRANSFERASES GST-4α, GST-4β, AND GST-6 |
| 01/25/2001 | WO2001006010A1 Antisense modulation of telomeric repeat binding factor 1 expression |
| 01/25/2001 | WO2001006005A2 Diagnostic method comprising wt1 sequences |
| 01/25/2001 | WO2001005998A1 Follistatin-3 |
| 01/25/2001 | WO2001005991A1 Scleroprotein of an adeno-associated virus with modified chromatographic properties, the production thereof and use of the same |
| 01/25/2001 | WO2001005990A1 Structural protein of adeno-associated virus with modified antigenicity, its production and its use |
| 01/25/2001 | WO2001005989A1 Method of constructing recombinant adenovirus vector |
| 01/25/2001 | WO2001005983A1 Dsp-11 dual-specificity map kinase phosphatase |
| 01/25/2001 | WO2001005970A2 Gtp-binding protein associated factors |
| 01/25/2001 | WO2001005967A1 Splice variants of cd40-receptor |
| 01/25/2001 | WO2001005966A1 Nucleic acids coding for peptides having the biological activity of sorbin |
| 01/25/2001 | WO2001005964A1 Inhibitor of osteoclast precursor formation |
| 01/25/2001 | WO2001005958A1 Antisense modulation of p13 kinase p110 delta expression |
| 01/25/2001 | WO2001005947A1 Melanin-concentrating hormone receptor |
| 01/25/2001 | WO2001005945A2 Packaging systems for human recombinant adenovirus to be used in gene therapy |
| 01/25/2001 | WO2001005943A2 Lcat recombinant cell line compositions and methods |
| 01/25/2001 | WO2001005940A2 Methods for producing and preparing cells for cell therapy |
| 01/25/2001 | WO2001005937A2 Conversion of a watson-crick dna to a hoogsteen-paired duplex |
| 01/25/2001 | WO2001005934A2 Feline calicivirus genes and vaccines, in particular recombined vaccines |
| 01/25/2001 | WO2001005834A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 01/25/2001 | WO2001005831A1 Modulation of human sodium channels in dorsal root ganglia |
| 01/25/2001 | WO2001005826A2 Chimeric polypeptides of serum albumin and uses related thereto |
| 01/25/2001 | WO2001005821A2 Viral il-10 for the inhibition of angiogenesis, tumorigenesis and metastasis |
| 01/25/2001 | WO2001005820A2 Method for down-regulating gdf-8 activity |
| 01/25/2001 | WO2001005802A1 Antisense modulation of fadd expression |
| 01/25/2001 | WO2001005480A2 Chemokine binding protein of gammaherpesvirus 68 and methods of use therefor |
| 01/25/2001 | WO2001005437A2 Methods for treatment of hyperproliferative diseases using human mda-7 |
| 01/25/2001 | WO2001005436A1 Method for producing antibodies in egg yolk and use of resulting antibodies |
| 01/25/2001 | WO2001005435A2 Antisense therapy for hormone-regulated tumors |
| 01/25/2001 | WO2001005432A2 Conjugate for mediating cell, compartment or membrane-specific transport of active substances |
| 01/25/2001 | WO2001005421A1 Methods employing bacterial toxin-antitoxin systems for killing eukaryotic cells |
| 01/25/2001 | WO2001005405A1 Folylpolyglutamyl synthetase gene transfer to enhance antifolate drug sensitivity |
| 01/25/2001 | WO2001005374A1 Methods for preparation of lipid-encapsulated therapeutic agents |
| 01/25/2001 | WO2001005373A1 Methods and apparatus for preparation of lipid vesicles |
| 01/25/2001 | WO2001005229A1 Non-defective epstein-barr viral vector |
| 01/25/2001 | WO2000071576A3 Adenovirus vectors encoding brain natriuretic peptide |
| 01/25/2001 | WO2000068399A3 Vector-mediated delivery of integrating transposon sequences |
| 01/25/2001 | WO2000065034A3 Pseudotyped retroviral vector for gene therapy of cancer |
| 01/25/2001 | WO2000065030A3 Microencapsulated genetically engineered e. coli dh 5 cells for the removal of undesired electrolytes and/or metabolites |
| 01/25/2001 | WO2000064930A3 Tribonectins |
| 01/25/2001 | WO2000062817A3 Inducible vaccines |
| 01/25/2001 | WO2000061156A3 Methods of treating schizophrenia |
| 01/25/2001 | WO2000058473A3 Nucleic acids including open reading frames encoding polypeptides; 'orfx' |
| 01/25/2001 | WO2000057837A3 Compositions and methods for effecting the levels of cholesterol |
| 01/25/2001 | WO2000053785A3 Method to improve translation of polypeptides by using untranslated regions from heat-shock proteins |
| 01/25/2001 | DE19936034C1 Linear DNA construct for neuron-specific expression, useful e.g. for gene therapy of neurodegenerative diseases, contains eukaryotic tumor suppressor gene |
| 01/25/2001 | DE19934029A1 Preparing an agent for diagnosis or control of microbial infection, useful particularly against Helicobacter, based on identification of essential genes in defective mutants |
| 01/25/2001 | DE19933719A1 Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung Structural protein in adeno-associated virus with altered the chromatographic properties, its preparation and use |
| 01/25/2001 | DE19930959A1 Neue Antimycotika und Fungizide, Verfahren zu deren Herstellung und Verwendung New antimycotics and fungicides, processes for their preparation and use |
| 01/25/2001 | CA2616704A1 Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease |
| 01/25/2001 | CA2381961A1 Splice variants of cd40-receptor |
| 01/25/2001 | CA2381327A1 Human tumor necrosis factor receptors tr13 and tr14 |
| 01/25/2001 | CA2379983A1 Dsp-11 dual-specificity map kinase phosphatase |
| 01/25/2001 | CA2379968A1 Gtp-binding protein associated factors |
| 01/25/2001 | CA2379852A1 Method for down-regulating gdf-8 activity |
| 01/25/2001 | CA2379825A1 Nucleic acids coding for peptides having the biological activity of sorbin |
| 01/25/2001 | CA2379618A1 Viral protein binding compositions and methods |
| 01/25/2001 | CA2379391A1 Modulation of human sodium channels in dorsal root ganglia |
| 01/25/2001 | CA2379325A1 Methods employing bacterial toxin-antitoxin systems for killing eukaryotic cells |
| 01/25/2001 | CA2379171A1 Methods for treatment of hyperproliferative diseases using human mda-7 |
| 01/25/2001 | CA2378917A1 Melanin-concentrating hormone receptor |
| 01/25/2001 | CA2378430A1 Methods and apparatus for preparation of lipid vesicles |
| 01/25/2001 | CA2378061A1 Packaging systems for human recombinant adenovirus to be used in gene therapy |
| 01/25/2001 | CA2378026A1 Novel glycosyl sulfotransferases gst-4.alpha., gst-4.beta., and gst-6 |
| 01/25/2001 | CA2377906A1 Methods for producing and preparing cells for cell therapy |
| 01/25/2001 | CA2376641A1 Chimeric polypeptides of serum albumin and uses related thereto |
| 01/25/2001 | CA2376518A1 Conversion of a watson-crick dna to a hoogsteen-paired duplex |
| 01/25/2001 | CA2375467A1 Antisense therapy for hormone-regulated tumors |
| 01/24/2001 | EP1070141A1 Immediate early genes and methods of use therefor |
| 01/24/2001 | EP1070140A1 Compositions and methods for treating cells having double minute dna |
| 01/24/2001 | EP1070133A2 Biological material with increased expression of endogenous complement regulatory molecules |
| 01/24/2001 | EP1070131A1 Ubiquitin conjugating enzyme |
| 01/24/2001 | EP1070125A2 Human nucleic acid sequences from normal breast tissue |
| 01/24/2001 | EP1070122A2 Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery |
| 01/24/2001 | EP1070118A1 Modified adenovirus containing a fiber replacement protein |
| 01/24/2001 | EP1069917A1 Novel complementing receptor-ligand pairs and adoptive immunotherapy using same |
| 01/24/2001 | EP1069908A2 Methods and modified cells for the treatment of cancer |
| 01/24/2001 | EP1069821A1 Method of controlling proliferation and differentiation of stem and progenitor cells |
| 01/24/2001 | EP0904392B1 Retroviral vectors |
| 01/24/2001 | CN1281512A Selective killing and diagnosis of P53+ neoplastic cells |
| 01/24/2001 | CN1281509A Human MDG1 gene (CBFAWB10) |
| 01/24/2001 | CN1281355A Biodegradable mixed polymeric micelles for gene delivery |
| 01/24/2001 | CN1281336A Treatment of neoplasms with viruses |
| 01/23/2001 | US6177554 Nucleic acid transporter systems |
| 01/23/2001 | US6177410 Therapeutic methods for prostate cancer |
| 01/23/2001 | US6177403 Compositions, methods, and apparatus for delivery of a macromolecular assembly to an extravascular tissue of an animal |
| 01/23/2001 | US6177402 Promoting survival of mammalian sensory neurons by contacting with leukemia inhibitory factor (lif) |
| 01/23/2001 | US6177274 Expression vector for transfering nucleotide sequences to liver cells; for the amplified efficiency of transformation and transfection of preferential cells |
| 01/23/2001 | US6177273 Antisense modulation of integrin-linked kinase expression |
| 01/23/2001 | US6177272 Method for treating vascular proliferative diseases with p27 and fusions thereof |
| 01/23/2001 | US6177246 Contacting a tissue or cell with an oligonucleotide of defined nucleotide sequence which hybridizes to nucleic acid encoding abnormally expressed beta-amyloid precursor protein; prophylaxis and treatment of alzheimer's disease |
| 01/23/2001 | US6177245 Manipulation of protoporphyrinogen oxidase enzyme activity in eukaryotic organisms |
| 01/23/2001 | US6177244 Oligonucleotide which hybridizes to nucleic acid of defined nucleotide sequence; diagnosis; drug screening; antitumor agents; antimetastasis agents |
| 01/18/2001 | WO2001004629A1 E4orf4 and pp2a polypeptides, modulators, and mimetics for selectively inducing cell death |
| 01/18/2001 | WO2001004334A2 Infection with chimaeric adenoviruses of cells negative for the adenovirus serotype 5 coxsacki adenovirus receptor (car) |
| 01/18/2001 | WO2001004332A1 Method to improve viral infection |
| 01/18/2001 | WO2001004326A1 Tankyrase homolog protein (thp), nucleic acids, and methods related to the same |